Scholar Rock Holding Corporation (SRRK)
Largest Insider Buys in Sector
SRRK Stock Price History Chart
SRRK Stock Performance
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as …
Insider Activity of Scholar Rock Holding Corporation
Over the last 12 months, insiders at Scholar Rock Holding Corporation have bought $0 and sold $128.79M worth of Scholar Rock Holding Corporation stock.
On average, over the past 5 years, insiders at Scholar Rock Holding Corporation have bought $23.78M and sold $45.72M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,189,781 shares for transaction amount of $15M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2023‑10‑16.
List of Insider Buy and Sell Transactions, Scholar Rock Holding Corporation
| 2024-12-10 | Sale | 10 percent owner | 1.6M 1.6035% | $41.65 | $66.64M | -4.48% | ||
| 2024-11-25 | Sale | 10 percent owner | 409,433 0.4461% | $38.49 | $15.76M | +11.13% | ||
| 2024-11-25 | Sale | CHIEF MEDICAL OFFICER | 6,375 0.0071% | $39.44 | $251,399 | +11.13% | ||
| 2024-11-22 | Sale | CHIEF MEDICAL OFFICER | 2,145 0.0023% | $30.01 | $64,372 | +39.91% | ||
| 2024-11-11 | Sale | CHIEF MEDICAL OFFICER | 2,105 0.0025% | $30.00 | $63,158 | +41.28% | ||
| 2024-10-08 | Sale | COO & CFO | 37,187 0.1874% | $34.90 | $1.3M | +1.59% | ||
| 2024-10-07 | Sale | director | 1.18M 4.967% | $29.25 | $34.39M | -12.66% | ||
| 2024-10-07 | Sale | COO & CFO | 206,240 0.7912% | $26.56 | $5.48M | -12.66% | ||
| 2024-10-07 | Sale | CHIEF MEDICAL OFFICER | 109,375 0.4299% | $27.21 | $2.98M | -12.66% | ||
| 2024-10-07 | Sale | CHIEF COMMERCIAL OFFICER | 30,000 0.111% | $25.62 | $768,677 | -12.66% | ||
| 2024-09-16 | Sale | CHIEF SCIENTIFIC OFFICER | 1,936 0.0026% | $8.58 | $16,611 | +258.52% | ||
| 2024-08-16 | Sale | CHRO | 1,451 0.0018% | $9.33 | $13,538 | +0.75% | ||
| 2024-06-17 | Sale | GENERAL COUNSEL | 4,695 0.0055% | $8.98 | $42,183 | +6.95% | ||
| 2024-06-17 | Sale | COO & CFO | 9,458 0.011% | $8.98 | $84,978 | +6.95% | ||
| 2024-06-17 | Sale | CHRO | 4,305 0.005% | $8.98 | $38,680 | +6.95% | ||
| 2024-06-17 | Sale | CHIEF SCIENTIFIC OFFICER | 2,315 0.0027% | $8.98 | $20,800 | +6.95% | ||
| 2024-02-16 | Sale | CHIEF EXECUTIVE OFFICER | 11,614 0.016% | $15.74 | $182,842 | -10.24% | ||
| 2024-02-16 | Sale | COO & CFO | 4,744 0.0065% | $15.74 | $74,686 | -10.24% | ||
| 2024-02-16 | Sale | GENERAL COUNSEL | 3,489 0.0048% | $15.74 | $54,928 | -10.24% | ||
| 2024-02-16 | Sale | CHRO | 3,751 0.0052% | $15.74 | $59,053 | -10.24% |
Insider Historical Profitability
| Invus Public Equities, L.P. | 10 percent owner | 9250005 9.8809% | $44.78 | 4 | 3 | +13.03% |
| AKKARAJU SRINIVAS | director | 5612896 5.9957% | $44.78 | 1 | 1 | |
| Invus Public Equities Advisors, LLC | director | 8850005 9.4536% | $44.78 | 2 | 0 | |
| Samsara BioCapital GP, LLC | 10 percent owner | 6788609 7.2516% | $44.78 | 1 | 0 | |
| SPRINGER TIMOTHY A | 3273519 3.4968% | $44.78 | 1 | 0 | +17.37% |
Institutional Investor Ownership
| Artal Group S A | $199.97M | 14.12 | 11.26M | 0% | +$0 | 0.87 | |
| Fidelity Investments | $188.3M | 13.29 | 10.6M | +1.8% | +$3.34M | 0.01 | |
| T. Rowe Price | $145.78M | 10.29 | 8.21M | -1.36% | -$2.01M | 0.02 | |
| Samsara Biocapital Llc | $120.57M | 8.51 | 6.79M | 0% | +$0 | 18.8 | |
| Redmile Group | $114.01M | 8.05 | 6.42M | +0.27% | +$303,784.80 | 1.16 |